↓ Skip to main content

Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression

Overview of attention for article published in Molecular Cancer, March 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression
Published in
Molecular Cancer, March 2014
DOI 10.1186/1476-4598-13-74
Pubmed ID
Authors

Lide Alaña, Marta Sesé, Verónica Cánovas, Yolanda Punyal, Yolanda Fernández, Ibane Abasolo, Inés de Torres, Cristina Ruiz, Lluís Espinosa, Anna Bigas, Santiago Ramón y Cajal, Pedro L Fernández, Florenci Serras, Montserrat Corominas, Timothy M Thomson, Rosanna Paciucci

Abstract

PTOV1 is an adaptor protein with functions in diverse processes, including gene transcription and protein translation, whose overexpression is associated with a higher proliferation index and tumor grade in prostate cancer (PC) and other neoplasms. Here we report its interaction with the Notch pathway and its involvement in PC progression.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Slovenia 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 20%
Student > Master 7 15%
Student > Ph. D. Student 7 15%
Student > Bachelor 5 11%
Student > Postgraduate 2 4%
Other 6 13%
Unknown 10 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 17%
Agricultural and Biological Sciences 8 17%
Medicine and Dentistry 5 11%
Neuroscience 3 7%
Computer Science 2 4%
Other 7 15%
Unknown 13 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2014.
All research outputs
#13,855,742
of 24,525,936 outputs
Outputs from Molecular Cancer
#861
of 1,840 outputs
Outputs of similar age
#108,810
of 231,065 outputs
Outputs of similar age from Molecular Cancer
#22
of 46 outputs
Altmetric has tracked 24,525,936 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,840 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 231,065 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.